AI Technology Group Signs Definitive Agreement to Acquire AVM Biotechnology

RENO, Nev., Oct. 10, 2025 (GLOBE NEWSWIRE) -- AI Technology Group Inc. (OTCID: AIPG) (the “Company”) announced that it has filed an amended Form 10 with the Securities and Exchange Commission and signed a definitive agreement dated July 31, 2025, to acquire AVM Biotechnology Inc. (“AVM”). Under the agreement, a newly formed subsidiary of Ai Technology Group will merge with AVM, and AVM will become a wholly owned subsidiary at closing, subject to customary closing conditions summarized in the filing. Following closing, the Company anticipates changing its corporate name and ticker symbol to align with the combined business, subject to regulatory approval.

About AVM Biotechnology

AVM Biotechnology is commercializing “AVM0703”, a fully developed small‑molecule drug, intended to fight all forms of cancer with a simple one‑hour outpatient infusion designed to re-activate the body’s Reserve Immune System, including bispecific gamma/delta TCR+ and invariant TCR+ T lymphocytes and Natural Killer T cells, which recognize and kill cancer and other abnormal cells in the body. AVM0703 also stimulates hematopoietic stem cell and mesenchymal stem cell production. It is room‑temperature stable with a 2-year shelf life, can be administered without the requirement of a comprehensive cancer center, and does not require cell engineering, radiation, or complex manufacturing. There have been no safety signals in 90 total subjects treated to date, even with repeat dosing out to 19 cycles. AVM0703 is a U.S. FDA investigational new drug application (IND) in Phase 2 human trials in relapsed/refractory non‑Hodgkin lymphoma (NHL) patients and in individual patient INDs for other blood cancers and various solid tumors. From preclinical and clinical research, AVM0703 also has broad applications to autoimmune diseases such as rheumatoid arthritis and diabetes, and to infectious disease.

Program snapshot (to date): Ninety (90) patients have been treated across the Phase 1b/2 clinical trial, FDA Expanded Access and global Compassionate Use, with over 250 total infusions. In FDA Expanded Access and global Compassionate Use, specifically, 60 patients with 20 different types of solid tumors or blood cancers, or with GvHD (graft vs host disease) or non-healing wounds or autoimmune disease have been treated with repeat dosing of up to 19 infusions per patient and no cumulative toxicity observed. Expanded Access and Compassionate Use provides real‑world data in heterogenous patient populations and better prediction of how a drug will work in real-life use.